1887

Abstract

Feline herpesvirus type-1 (FHV-1) is the most common viral cause of ocular surface disease in cats. Many antiviral drugs are used to treat FHV-1, but require frequent topical application and most lack well-controlled studies to justify their clinical use. Therefore, better validation of current and novel treatment options are urgently needed. Here, we report on the development of a feline whole corneal explant model that supports FHV-1 replication and thus can be used as a novel model system to evaluate the efficacy of antiviral drugs. The anti-herpes nucleoside analogues cidofovir and acyclovir, which are used clinically to treat ocular herpesvirus infection in cats and have previously been evaluated in traditional two-dimensional feline cell cultures , were evaluated in this explant model. Both drugs suppressed FHV-1 replication when given every 12 h, with cidofovir showing greater efficacy. In addition, the potential efficacy of the retroviral integrase inhibitor raltegravir against FHV-1 was evaluated in cell culture as well as in the explant model. Raltegravir was not toxic to feline cells or corneas, and most significantly, inhibited FHV-1 replication at 500 µM in both systems. Importantly, this drug was effective when given only once every 24 h. Taken together, our data indicate that the feline whole corneal explant model is a useful tool for the evaluation of antiviral drugs and, furthermore, that raltegravir appears a promising novel antiviral drug to treat ocular herpesvirus infection in cats.

Loading

Article metrics loading...

/content/journal/jgv/10.1099/jgv.0.000451
2016-06-01
2020-04-04
Loading full text...

Full text loading...

/deliver/fulltext/jgv/97/6/1414.html?itemId=/content/journal/jgv/10.1099/jgv.0.000451&mimeType=html&fmt=ahah

References

  1. Alekseev O., Tran A. H., Azizkhan-Clifford J.. 2012; Ex vivo organotypic corneal model of acute epithelial herpes simplex virus type I infection. J Vis Exp69:e3631 [CrossRef][PubMed]
    [Google Scholar]
  2. Astashkina A., Mann B., Grainger D. W.. 2012; A critical evaluation of in vitro cell culture models for high-throughput drug screening and toxicity. Pharmacol Ther134:82–106 [CrossRef][PubMed]
    [Google Scholar]
  3. Boesch A., Cattori V., Riond B., Willi B., Meli M. L., Rentsch K. M., Hosie M. J., Hofmann-Lehmann R., Lutz H.. 2015; Evaluation of the effect of short-term treatment with the integrase inhibitor raltegravir (Isentress™) on the course of progressive feline leukemia virus infection. Vet Microbiol175:167–178 [CrossRef][PubMed]
    [Google Scholar]
  4. Cundy K. C., Petty B. G., Flaherty J., Fisher P. E., Polis M. A., Wachsman M., Lietman P. S., Lalezari J. P., Hitchcock M. J., Jaffe H. S.. 1995; Clinical pharmacokinetics of cidofovir in human immunodeficiency virus-infected patients. Antimicrob Agents Chemother39:1247–1252[PubMed]
    [Google Scholar]
  5. Daviaud N., Garbayo E., Schiller P. C., Perez-Pinzon M., Montero-Menei C. N.. 2013; Organotypic cultures as tools for optimizing central nervous system cell therapies. Exp Neurol248:429–440 [CrossRef]
    [Google Scholar]
  6. Davison A. J., Eberle R., Ehlers B., Hayward G. S., McGeoch D. J., Minson A. C., Pellett P. E., Roizman B., Studdert M. J., Thiry E.. 2009; The order Herpesvirales. Arch Virol154:171–177 [CrossRef][PubMed]
    [Google Scholar]
  7. Fontenelle J. P., Powell C. C., Veir J. K., Radecki S. V., Lappin M. R.. 2008; Effect of topical ophthalmic application of cidofovir on experimentally induced primary ocular feline herpesvirus-1 infection in cats. Am J Vet Res69:289–293 [CrossRef][PubMed]
    [Google Scholar]
  8. Galle L. E.. 2004; Antiviral therapy for ocular viral disease. Vet Clin Small Anim34:639–653 [CrossRef]
    [Google Scholar]
  9. Gaskell R. M., Povey R. C.. 1977; Experimental induction of feline viral rhinotracheitis virus re-excretion in FVR-recovered cats. Vet Rec100:128–133[PubMed]
    [Google Scholar]
  10. Gaskell R., Dawson S., Radford A., Thiry E.. 2007; Feline herpesvirus. Vet Res38:337–354 [CrossRef][PubMed]
    [Google Scholar]
  11. Gould D.. 2011; Feline herpesvirus-1: ocular manifestations, diagnosis and treatment options. J Feline Med Surg13:333–346 [CrossRef][PubMed]
    [Google Scholar]
  12. Grivel J. C., Margolis L.. 2009; Use of human tissue explants to study human infectious agents. Nat Protoc4:256–269 [CrossRef]
    [Google Scholar]
  13. Groth A. D., Contreras M. T., Kado-Fong H. K., Nguyen K. Q., Thomasy S. M., Maggs D. J.. 2014; In vitro cytotoxicity and antiviral efficacy against feline herpesvirus type 1 of famciclovir and its metabolites. Vet Ophthalmol17:268–274 [CrossRef][PubMed]
    [Google Scholar]
  14. Hare S., Gupta S. S., Valkov E., Engelman A., Cherepanov P.. 2010; Retroviral intasome assembly and inhibition of DNA strand transfer. Nature464:232–236 [CrossRef][PubMed]
    [Google Scholar]
  15. Harman R. M., Bussche L., Ledbetter E. C., Van de Walle G. R.. 2014; Establishment and characterization of an air-liquid canine corneal organ culture model to study acute herpes keratitis. J Virol88:13669–13677 [CrossRef][PubMed]
    [Google Scholar]
  16. Hicks C., Gulick R. M.. 2009; Raltegravir: the first HIV type 1 integrase inhibitor. Clin Infect Dis48:931–939 [CrossRef][PubMed]
    [Google Scholar]
  17. Kimberlin D. W., Whitley R. J.. 2007; Antiviral therapy of HSV-1 and -2. In Human Herpesviruses: Biology, Therapy, and Immunoprophylaxis, Chapter 64 pp.1153–1174 Edited by Arvin A., other editors. Cambridge: Cambridge University Press; [CrossRef]
    [Google Scholar]
  18. Kola I., Landis J.. 2004; Can the pharmaceutical industry reduce attrition rates?. Nat Rev Drug Discov3:711–716 [CrossRef][PubMed]
    [Google Scholar]
  19. Ledbetter E. C., Spertus C. B., Pennington M. R., Van de Walle G. R., Judd B. E., Mohammed H. O.. 2015; In vitro and in vivo evaluation of cidofovir as a topical ophthalmic antiviral for ocular canine herpesvirus infections in dogs. J Ocul Pharmacol Ther31:642–649 [CrossRef][PubMed]
    [Google Scholar]
  20. Leushacke M., Barker N.. 2014; Ex vivo culture of the intestinal epithelium: strategies and applications. Gut63:1345–1354 [CrossRef][PubMed]
    [Google Scholar]
  21. Li Y., Van Cleemput J., Qiu Y., Reddy V. R., Mateusen B., Nauwynck H. J.. 2015; Ex vivo modeling of feline herpesvirus replication in ocular and respiratory mucosae, the primary targets of infection. Virus Res210:227–231 [CrossRef][PubMed]
    [Google Scholar]
  22. Maggs D. J., Lappin M. R., Reif J. S., Collins J. K., Carman J., Dawson D. A., Bruns C.. 1999; Evaluation of serologic and viral detection methods for diagnosing feline herpesvirus-1 infection in cats with acute respiratory tract or chronic ocular disease. J Am Vet Med Assoc214:502–507[PubMed]
    [Google Scholar]
  23. Maggs D. J., Clarke H. E.. 2004; In vitro efficacy of ganciclovir, cidofovir, penciclovir, foscarnet, idoxuridine, and acyclovir against feline herpesvirus type-1. Am J Vet Res65:399–403[PubMed]
    [Google Scholar]
  24. Maggs D. J.. 2010; Antiviral therapy for feline herpesvirus infections. Vet Clin Small Anim40:1055–1062 [CrossRef]
    [Google Scholar]
  25. Mathes S. H., Ruffner H., Graf-Hausner U.. 2014; The use of skin models in drug development. Adv Drug Deliv Rev69-70:81–102 [CrossRef][PubMed]
    [Google Scholar]
  26. Nasisse M. P., Guy J. S., Davidson M. G., Sussman W. A., Fairley N. M.. 1989; Experimental ocular herpesvirus infection in the cat. Invest Ophthalmol Vis Sci30:1758–1768[PubMed]
    [Google Scholar]
  27. Nasisse M. P., Dorman D. C., Jamison K. C., Weigler B. J., Hawkins E. C., Stevens J. B.. 1997; Effects of valacyclovir in cats infected with feline herpesvirus 1. Am J Vet Res58:1141–1144[PubMed]
    [Google Scholar]
  28. Rand J.. 2006; Part 1: Cat with upper respiratory tract signs.. Problem-Based Feline Medicine9 Philadelphia, PA: Elsevier Health Sciences;
    [Google Scholar]
  29. Resau J. H., Sakamoto K., Cottrell J. R., Hudson E. A., Meltzer S. J.. 1991; Explant organ culture: a review. Cytotechnology7:137–149[PubMed]
    [Google Scholar]
  30. Roh H. D., Goldstick T. K., Linsenmeier R. A.. 1990; Spatial variation of the local tissue oxygen diffusion coefficient measured in situ in the cat retina and cornea. Adv Exp Med Biol277:127–136[PubMed]
    [Google Scholar]
  31. Russell W. M. S., Burch R. L.. 1959; The Principles of Humane Experimental Technique London: Methuen;
    [Google Scholar]
  32. Sangdara A., Bhattarakosol P.. 2008; Acyclovir susceptibility of herpes simplex virus isolates at King Chulalongkorn Memorial Hospital, Bangkok. J Med Assoc Thai91:908–912[PubMed]
    [Google Scholar]
  33. Stiles J.. 2014; Ocular manifestations of feline viral diseases. Vet J201:166–173 [CrossRef][PubMed]
    [Google Scholar]
  34. Summa V., Petrocchi A., Bonelli F., Crescenzi B., Donghi M., Ferrara M., Fiore F., Gardelli C., Gonzalez Paz O., other authors. 2008; Discovery of raltegravir, a potent, selective orally bioavailable HIV-integrase inhibitor for the treatment of HIV-AIDS infection. J Med Chem51:5843–5855 [CrossRef][PubMed]
    [Google Scholar]
  35. Walton T. E., Gillespie J. H.. 1970; Feline viruses. VII. Immunity to the feline herpesvirus in kittens inoculated experimentally by the aerosol method. Cornell Vet60:232–239[PubMed]
    [Google Scholar]
  36. Williams D. L., Robinson J. C., Lay E., Field H.. 2005; Efficacy of topical aciclovir for the treatment of feline herpetic keratitis: results of a prospective clinical trial and data from in vitro investigations. Vet Rec157:254–257 [CrossRef][PubMed]
    [Google Scholar]
  37. Yan Z., Bryant K. F., Gregory S. M., Angelova M., Dreyfus D. H., Zhao X. Z., Coen D. M., Burke T. R., Knipe D. M.. 2014; HIV integrase inhibitors block replication of alpha-, beta-, and gammaherpesviruses. mBio5:e01318–14 [CrossRef][PubMed]
    [Google Scholar]
  38. Zhou B., Yang K., Wills E., Tang L., Baines J. D.. 2014; A mutation in the DNA polymerase accessory factor of herpes simplex virus 1 restores viral DNA replication in the presence of raltegravir. J Virol88:11121–11129 [CrossRef][PubMed]
    [Google Scholar]
  39. Zhukovskaya N. L., Guan H., Saw Y. L., Nuth M., Ricciardi R. P.. 2015; The processivity factor complex of feline herpes virus-1 is a new drug target. Antiviral Res115:17–20 [CrossRef][PubMed]
    [Google Scholar]
http://instance.metastore.ingenta.com/content/journal/jgv/10.1099/jgv.0.000451
Loading
/content/journal/jgv/10.1099/jgv.0.000451
Loading

Data & Media loading...

Most cited this month

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error